الفهرس 
Therapeutic role of bone marrow-derived mesenchymal stem cells in controlling prognosis of hepatocellular carcinoma in murine model
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death in the world.The extremely poor prognosis of HCC is largely due to the high rate of intra-hepatic metastases that develop through invasion of the portal vein and spread to other parts of the liver.Therefore, exploring new therapeutic strategies to control the progression of HCC is the key issue for prolonging patient survival. Animal models for HCC can be helpful to understand the mechanisms underlying the pathogenesis of HCC, which may offer new insights for possible treatment options.Use of stem cells to cure liver diseases has been proved beneficial in most of the conditions.Stem cells possess the ability to renew and multiply as well as the ability to differentiate into any tissue type. Mesenchymal stromal (stem) cells (MSCs) are more often obtained from adult and extraembryonic tissues, bone marrow tissue for example. Mesenchymal stem cells (MSCs) can have an effect on the growth and metastasis of human malignancies, including hepatocellular carcinoma (HCC). Forty albino female rats of about six months age and weighing between 120-150 gm were divided into three groups: group A: normal uninfected negative control rats. group B:14 rats intraperitonially injected with Diethylnitrosamine (DEN) weekly for twelve weeks and were not subjected to bone marrow stem cells inoculation. group C: 14 rats intraperitonially injected with Diethylnitrosamine (DEN) weekly for twelve weeks and were subjected to treatment with BMMSCs (1 million cells/rat), respectively on the 14th week after the first injection. group C was monitored for three months after BMMSCs injection